What is the current valuation of the Thumb Arthritis Market?

The Thumb Arthritis Market was valued at 466.56 USD Million in 2024. Read More

What is the projected market size for the Thumb Arthritis Market by 2035?

The market is expected to reach 1144.78 USD Million by 2035. Read More

What is the expected CAGR for the Thumb Arthritis Market during the forecast period?

The expected CAGR for the Thumb Arthritis Market from 2025 to 2035 is 8.5%. Read More

Which types of arthritis are included in the Thumb Arthritis Market segmentation?

The market segments include Osteoarthritis, Rheumatoid Arthritis, Post-Traumatic Arthritis, and Gout. Read More

What were the market values for Osteoarthritis and Rheumatoid Arthritis in 2024?

In 2024, Osteoarthritis was valued at 186.56 USD Million, while Rheumatoid Arthritis was valued at 120.0 USD Million. Read More

How does the market for assistive devices compare to other treatment types?

Assistive Devices were valued at 93.31 USD Million in 2024, similar to Physical Therapy and Surgical Intervention. Read More

What age groups are represented in the Thumb Arthritis Market?

The market segments by age group include Children, Adults, and the Elderly. Read More

What were the market values for the elderly and adults in 2024?

In 2024, the market value for the Elderly was 166.56 USD Million, while Adults accounted for 250.0 USD Million. Read More

Which companies are considered key players in the Thumb Arthritis Market?

Key players include Johnson & Johnson, Medtronic, Stryker Corporation, and Zimmer Biomet. Read More

What severity levels are recognized in the Thumb Arthritis Market?

The market recognizes Mild, Moderate, and Severe severity levels, with Moderate valued at 186.88 USD Million in 2024. Read More

Thumb Arthritis Market

Thumb Arthritis Market Research Report Information By Diagnosis (Physical Examinations, Imaging, FNA), By Type (Osteoarthritis, Rheumatoid), By Treatment (Thumb Exercise, Medication, Surgery), By End Users (Hospitals & Clinics, Retail Pharmacies), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035

Forecast Period

2025 - 2035

CAGR

8.5%

2024 Market Size

$ 466.56 Million

2035 Market Size

$ 1,144.78 Million

Medical Device ● Updated May 2026 Report ID: MRFR/MED/3800-HCR | Pages: 90 | Author: Rahul Gotadki, Kinjoll Dey

Summary Table of Contents Segmentation Methodology Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Type of Arthritis (USD Million)
  1. 4.1.1 Osteoarthritis
  2. 4.1.2 Rheumatoid Arthritis
  3. 4.1.3 Post-Traumatic Arthritis
  4. 4.1.4 Gout
2. 4.2 Healthcare, BY Treatment Type (USD Million)
  1. 4.2.1 Medication
  2. 4.2.2 Physical Therapy
  3. 4.2.3 Surgical Intervention
  4. 4.2.4 Assistive Devices
3. 4.3 Healthcare, BY Age Group (USD Million)
  1. 4.3.1 Children
  2. 4.3.2 Adults
  3. 4.3.3 Elderly
4. 4.4 Healthcare, BY Severity Level (USD Million)
  1. 4.4.1 Mild
  2. 4.4.2 Moderate
  3. 4.4.3 Severe
5. 4.5 Healthcare, BY Region (USD Million)
  1. 4.5.1 North America
    1. 4.5.1.1 US
    2. 4.5.1.2 Canada
  2. 4.5.2 Europe
    1. 4.5.2.1 Germany
    2. 4.5.2.2 UK
    3. 4.5.2.3 France
    4. 4.5.2.4 Russia
    5. 4.5.2.5 Italy
    6. 4.5.2.6 Spain
    7. 4.5.2.7 Rest of Europe
  3. 4.5.3 APAC
    1. 4.5.3.1 China
    2. 4.5.3.2 India
    3. 4.5.3.3 Japan
    4. 4.5.3.4 South Korea
    5. 4.5.3.5 Malaysia
    6. 4.5.3.6 Thailand
    7. 4.5.3.7 Indonesia
    8. 4.5.3.8 Rest of APAC
  4. 4.5.4 South America
    1. 4.5.4.1 Brazil
    2. 4.5.4.2 Mexico
    3. 4.5.4.3 Argentina
    4. 4.5.4.4 Rest of South America
  5. 4.5.5 MEA
    1. 4.5.5.1 GCC Countries
    2. 4.5.5.2 South Africa
    3. 4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Johnson & Johnson (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Medtronic (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Stryker Corporation (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Zimmer Biomet (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Abbott Laboratories (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Baxter International (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Smith & Nephew (GB)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Boston Scientific (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 DePuy Synthes (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY TYPE OF ARTHRITIS
4. 6.4 US MARKET ANALYSIS BY TREATMENT TYPE
5. 6.5 US MARKET ANALYSIS BY AGE GROUP
6. 6.6 US MARKET ANALYSIS BY SEVERITY LEVEL
7. 6.7 CANADA MARKET ANALYSIS BY TYPE OF ARTHRITIS
8. 6.8 CANADA MARKET ANALYSIS BY TREATMENT TYPE
9. 6.9 CANADA MARKET ANALYSIS BY AGE GROUP
10. 6.10 CANADA MARKET ANALYSIS BY SEVERITY LEVEL
11. 6.11 EUROPE MARKET ANALYSIS
12. 6.12 GERMANY MARKET ANALYSIS BY TYPE OF ARTHRITIS
13. 6.13 GERMANY MARKET ANALYSIS BY TREATMENT TYPE
14. 6.14 GERMANY MARKET ANALYSIS BY AGE GROUP
15. 6.15 GERMANY MARKET ANALYSIS BY SEVERITY LEVEL
16. 6.16 UK MARKET ANALYSIS BY TYPE OF ARTHRITIS
17. 6.17 UK MARKET ANALYSIS BY TREATMENT TYPE
18. 6.18 UK MARKET ANALYSIS BY AGE GROUP
19. 6.19 UK MARKET ANALYSIS BY SEVERITY LEVEL
20. 6.20 FRANCE MARKET ANALYSIS BY TYPE OF ARTHRITIS
21. 6.21 FRANCE MARKET ANALYSIS BY TREATMENT TYPE
22. 6.22 FRANCE MARKET ANALYSIS BY AGE GROUP
23. 6.23 FRANCE MARKET ANALYSIS BY SEVERITY LEVEL
24. 6.24 RUSSIA MARKET ANALYSIS BY TYPE OF ARTHRITIS
25. 6.25 RUSSIA MARKET ANALYSIS BY TREATMENT TYPE
26. 6.26 RUSSIA MARKET ANALYSIS BY AGE GROUP
27. 6.27 RUSSIA MARKET ANALYSIS BY SEVERITY LEVEL
28. 6.28 ITALY MARKET ANALYSIS BY TYPE OF ARTHRITIS
29. 6.29 ITALY MARKET ANALYSIS BY TREATMENT TYPE
30. 6.30 ITALY MARKET ANALYSIS BY AGE GROUP
31. 6.31 ITALY MARKET ANALYSIS BY SEVERITY LEVEL
32. 6.32 SPAIN MARKET ANALYSIS BY TYPE OF ARTHRITIS
33. 6.33 SPAIN MARKET ANALYSIS BY TREATMENT TYPE
34. 6.34 SPAIN MARKET ANALYSIS BY AGE GROUP
35. 6.35 SPAIN MARKET ANALYSIS BY SEVERITY LEVEL
36. 6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE OF ARTHRITIS
37. 6.37 REST OF EUROPE MARKET ANALYSIS BY TREATMENT TYPE
38. 6.38 REST OF EUROPE MARKET ANALYSIS BY AGE GROUP
39. 6.39 REST OF EUROPE MARKET ANALYSIS BY SEVERITY LEVEL
40. 6.40 APAC MARKET ANALYSIS
41. 6.41 CHINA MARKET ANALYSIS BY TYPE OF ARTHRITIS
42. 6.42 CHINA MARKET ANALYSIS BY TREATMENT TYPE
43. 6.43 CHINA MARKET ANALYSIS BY AGE GROUP
44. 6.44 CHINA MARKET ANALYSIS BY SEVERITY LEVEL
45. 6.45 INDIA MARKET ANALYSIS BY TYPE OF ARTHRITIS
46. 6.46 INDIA MARKET ANALYSIS BY TREATMENT TYPE
47. 6.47 INDIA MARKET ANALYSIS BY AGE GROUP
48. 6.48 INDIA MARKET ANALYSIS BY SEVERITY LEVEL
49. 6.49 JAPAN MARKET ANALYSIS BY TYPE OF ARTHRITIS
50. 6.50 JAPAN MARKET ANALYSIS BY TREATMENT TYPE
51. 6.51 JAPAN MARKET ANALYSIS BY AGE GROUP
52. 6.52 JAPAN MARKET ANALYSIS BY SEVERITY LEVEL
53. 6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE OF ARTHRITIS
54. 6.54 SOUTH KOREA MARKET ANALYSIS BY TREATMENT TYPE
55. 6.55 SOUTH KOREA MARKET ANALYSIS BY AGE GROUP
56. 6.56 SOUTH KOREA MARKET ANALYSIS BY SEVERITY LEVEL
57. 6.57 MALAYSIA MARKET ANALYSIS BY TYPE OF ARTHRITIS
58. 6.58 MALAYSIA MARKET ANALYSIS BY TREATMENT TYPE
59. 6.59 MALAYSIA MARKET ANALYSIS BY AGE GROUP
60. 6.60 MALAYSIA MARKET ANALYSIS BY SEVERITY LEVEL
61. 6.61 THAILAND MARKET ANALYSIS BY TYPE OF ARTHRITIS
62. 6.62 THAILAND MARKET ANALYSIS BY TREATMENT TYPE
63. 6.63 THAILAND MARKET ANALYSIS BY AGE GROUP
64. 6.64 THAILAND MARKET ANALYSIS BY SEVERITY LEVEL
65. 6.65 INDONESIA MARKET ANALYSIS BY TYPE OF ARTHRITIS
66. 6.66 INDONESIA MARKET ANALYSIS BY TREATMENT TYPE
67. 6.67 INDONESIA MARKET ANALYSIS BY AGE GROUP
68. 6.68 INDONESIA MARKET ANALYSIS BY SEVERITY LEVEL
69. 6.69 REST OF APAC MARKET ANALYSIS BY TYPE OF ARTHRITIS
70. 6.70 REST OF APAC MARKET ANALYSIS BY TREATMENT TYPE
71. 6.71 REST OF APAC MARKET ANALYSIS BY AGE GROUP
72. 6.72 REST OF APAC MARKET ANALYSIS BY SEVERITY LEVEL
73. 6.73 SOUTH AMERICA MARKET ANALYSIS
74. 6.74 BRAZIL MARKET ANALYSIS BY TYPE OF ARTHRITIS
75. 6.75 BRAZIL MARKET ANALYSIS BY TREATMENT TYPE
76. 6.76 BRAZIL MARKET ANALYSIS BY AGE GROUP
77. 6.77 BRAZIL MARKET ANALYSIS BY SEVERITY LEVEL
78. 6.78 MEXICO MARKET ANALYSIS BY TYPE OF ARTHRITIS
79. 6.79 MEXICO MARKET ANALYSIS BY TREATMENT TYPE
80. 6.80 MEXICO MARKET ANALYSIS BY AGE GROUP
81. 6.81 MEXICO MARKET ANALYSIS BY SEVERITY LEVEL
82. 6.82 ARGENTINA MARKET ANALYSIS BY TYPE OF ARTHRITIS
83. 6.83 ARGENTINA MARKET ANALYSIS BY TREATMENT TYPE
84. 6.84 ARGENTINA MARKET ANALYSIS BY AGE GROUP
85. 6.85 ARGENTINA MARKET ANALYSIS BY SEVERITY LEVEL
86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE OF ARTHRITIS
87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT TYPE
88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY AGE GROUP
89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY SEVERITY LEVEL
90. 6.90 MEA MARKET ANALYSIS
91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE OF ARTHRITIS
92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT TYPE
93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY AGE GROUP
94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY SEVERITY LEVEL
95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE OF ARTHRITIS
96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT TYPE
97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY AGE GROUP
98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY SEVERITY LEVEL
99. 6.99 REST OF MEA MARKET ANALYSIS BY TYPE OF ARTHRITIS
100. 6.100 REST OF MEA MARKET ANALYSIS BY TREATMENT TYPE
101. 6.101 REST OF MEA MARKET ANALYSIS BY AGE GROUP
102. 6.102 REST OF MEA MARKET ANALYSIS BY SEVERITY LEVEL
103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
104. 6.104 RESEARCH PROCESS OF MRFR
105. 6.105 DRO ANALYSIS OF HEALTHCARE
106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
109. 6.109 HEALTHCARE, BY TYPE OF ARTHRITIS, 2024 (% SHARE)
110. 6.110 HEALTHCARE, BY TYPE OF ARTHRITIS, 2024 TO 2035 (USD Million)
111. 6.111 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
112. 6.112 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
113. 6.113 HEALTHCARE, BY AGE GROUP, 2024 (% SHARE)
114. 6.114 HEALTHCARE, BY AGE GROUP, 2024 TO 2035 (USD Million)
115. 6.115 HEALTHCARE, BY SEVERITY LEVEL, 2024 (% SHARE)
116. 6.116 HEALTHCARE, BY SEVERITY LEVEL, 2024 TO 2035 (USD Million)
117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
  2. 7.2.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
  3. 7.2.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.2.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
  2. 7.3.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
  3. 7.3.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.3.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
  2. 7.4.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
  3. 7.4.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.4.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
  2. 7.5.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
  3. 7.5.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.5.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
  2. 7.6.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
  3. 7.6.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.6.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
  2. 7.7.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
  3. 7.7.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.7.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
  2. 7.8.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
  3. 7.8.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.8.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
  2. 7.9.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
  3. 7.9.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.9.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
  2. 7.10.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
  3. 7.10.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.10.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
  2. 7.11.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
  3. 7.11.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.11.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
  2. 7.12.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
  3. 7.12.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.12.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
  2. 7.13.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
  3. 7.13.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.13.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
  2. 7.14.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
  3. 7.14.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.14.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
  2. 7.15.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
  3. 7.15.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.15.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
  2. 7.16.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
  3. 7.16.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.16.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
  2. 7.17.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
  3. 7.17.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.17.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
  2. 7.18.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
  3. 7.18.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.18.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
  2. 7.19.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
  3. 7.19.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.19.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
  2. 7.20.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
  3. 7.20.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.20.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
  2. 7.21.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
  3. 7.21.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.21.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
  2. 7.22.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
  3. 7.22.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.22.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
  2. 7.23.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
  3. 7.23.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.23.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
  2. 7.24.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
  3. 7.24.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.24.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
  2. 7.25.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
  3. 7.25.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.25.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
  2. 7.26.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
  3. 7.26.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.26.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
  2. 7.27.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
  3. 7.27.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.27.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
  2. 7.28.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
  3. 7.28.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.28.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
  2. 7.29.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
  3. 7.29.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.29.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Million)
  2. 7.30.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
  3. 7.30.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.30.4 BY SEVERITY LEVEL, 2025-2035 (USD Million)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Thumb Arthritis Market Segmentation

Thumb Arthritis Market By Type of Arthritis (USD Million, 2025-2035)

Osteoarthritis
Rheumatoid Arthritis
Post-Traumatic Arthritis
Gout

Thumb Arthritis Market By Treatment Type (USD Million, 2025-2035)

Medication
Physical Therapy
Surgical Intervention
Assistive Devices

Thumb Arthritis Market By Age Group (USD Million, 2025-2035)

Children
Adults
Elderly

Thumb Arthritis Market By Severity Level (USD Million, 2025-2035)

Mild
Moderate
Severe

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”